RT Journal Article
SR Electronic
T1 Clinical and immunoserological status 12 weeks after infection with COVID-19: prospective observational study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.10.06.20206060
DO 10.1101/2020.10.06.20206060
A1 Santis, Lucía Valiente-De
A1 Pérez-Camacho, Inés
A1 Sobrino, Beatriz
A1 González, Gracia Eugenia
A1 Ruíz-Mesa, Juan Diego
A1 Plata, Antonio
A1 Márquez-Gómez, Ignacio
A1 Delgado-Fernández, Marcial
A1 Castaño, Manuel
A1 Oñate, Francisco
A1 Orihuela, Francisco
A1 Palop, Begoña
A1 María Reguera, José
YR 2020
UL http://medrxiv.org/content/early/2020/10/08/2020.10.06.20206060.abstract
AB Objectives to undertake a multidisciplinary follow-up at 12 weeks after an acute episode of COVID-19 to assess the functional status, persistence of symptoms and immunoserological situation.Methods this prospective, observational, single-centre study included outpatients reviewed 12 weeks after an acute infection with SARS-CoV-2. The clinical evaluation included data about the acute episode and epidemiological and clinical variables. The patients were classified as symptomatic or asymptomatic depending on the persistence or otherwise of symptoms. All the patients underwent a full blood test and serology for SARS-CoV-2, as well as imaging tests and spirometry if needed.Results The mean age of the 108 patients was 55.5 (SD: 15.4) years and 27.8% were health-care workers; 75.9% presented some type of symptoms, with dyspnoea being the most common. A D-dimer >500 ng/mL was detected in 32 (31.4%) patients. All the patients had antibodies against SARS-CoV-2. Being a health-care worker was associated with symptom persistence, with age ≥65 years being a protective factor.Conclusions The persistence of symptoms in patents with COVID is usual 12 weeks after the acute episode, especially in patients <65 years and health-care workers. All our patients had developed antibodies by 12 weeks.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external funding was receivedAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by Comite de Etica de la Investigacion Provincial de MalagaAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesRegional University Hospital of Malaga